Poster Presentation 32nd Lorne Cancer 2020

Novel diagnostic biomarkers in prostate cancer (#334)

Luke T Quigley 1 2 3 , Jyotsna Batra 4 , Andreas Behren 1 5 , Jessica Da Gama Duarte 1 5
  1. Tumour Immunology Lab, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
  2. Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Bundoora, VIC, Australia
  3. Tumour Immunology Lab, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
  4. Translational Research Institute, Queensland University of Technology, Buranda, VIC, Australia
  5. School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia
Publish consent withheld
  1. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet (London, England) [Internet]. 2016 Jan 2;387(10013):70–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26074382
  2. Adeola HA, Smith M, Kaestner L, Blackburn JM, Zerbini LF. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort. Oncotarget. 2016;7(12):13945–64.
  3. Beeton-Kempen N, Duarte J, Shoko A, Serufuri JM, John T, Cebon J, et al. Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. Int J Cancer. 2014;135(8):1842–51.
  4. Da Gama Duarte J, Goosen RW, Lawry PJ, Blackburn JM. PMA: Protein Microarray Analyser, a user-friendly tool for data processing and normalization. BMC Res Notes. 2018 Feb 27;11(1):156.